New generation vaccines capable of eradicating variant strains of coronavirus are expected to be approved by the regulatory authorities of Britain, Australia, Switzerland, Canada and Singapore in an expedited procedure, in accordance with a recommendation combines the drug services of these countries.
“The approved vaccines against COVID-19“, modified to meet the new variants, will not require new approval or ‘long’ clinical trials,” said in a statement the British agency MHRA, which is linked through the ACCESS consortium to the regulatory authorities of four other countries – Australia. , Canada, Singapore and Switzerland.
This approach based on the procedure already in place for seasonal influenza vaccines, which are modified every year in order to deal with new strains of the virus, as explained by AMPE.
Vaccine manufacturers should therefore provide “solid evidence” of the immune response elicited by the modified vaccine, without undergoing “time-consuming” clinical trials. They should also demonstrate that the new product is “safe and of the required quality”, with regulators being able to base their decision on initial large-scale trials and ongoing research into the effects of vaccines given to the general population.
“Our priority is to deliver effective vaccines to the public as soon as possible, without compromising safety,” MHRA Scientific Director Christian Snyder said in a statement.
Britain, the country with the highest death toll in Europe – almost 124,000 – has launched one of the most advanced coronavirus vaccination campaigns in the world, with almost 21 million people already receiving a first dose since early December. He is counting on her in order to gradually lift the strict in the coming months lockdown effective from the beginning of January.
Experts fear, however, that variant strains, especially those first identified in Brazil and from which many infections have been reported in the country, are more resistant to the vaccines currently being administered.
The AstraZeneca pharmaceutical group in particular, which developed a vaccine with the University of Oxford, has stated that working on a new version in order to deal with the new variant strains, hoping to be ready in the fall.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
